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Introduction
Platinum-based compounds were first synthesized in the 
nineteenth century and their clinical use against cancer 
started in the 1970s (1,2). These drugs have been approved 
for the treatment of numerous malignancies, such as ovar-
ian, primary peritoneal carcinoma, bladder, head and 
neck, colorectal, pancreatic, esophageal, gastric, testicular, 
endometrial, biliary tract, lung cancer, and mesothelioma 
(3). Cisplatin was the first of the platinum drugs to be 
used (1). Second-generation platinum derivative carbo-
platin differs from cisplatin in the substitution of 2 chlo-
rides. Its efficacy in the treatment of many of the above 
malignancies is equal to that of cisplatin, and its toxicity 
profile is more favorable. Therefore, carboplatin has often 
been used in place of cisplatin (4,5). Cisplatin has some 
toxicity and adverse effects such as nausea, vomiting, an-
orexia, diarrhea, constipation, tinnitus, taste alteration, 
alopecia, hypocalcaemia, nephrotoxicity, and peripheral 
neurotoxicity (6,7). Several side effects of cisplatin such 
as hypersensitivity and electrolyte disturbance are uncom-
mon (8,9). Hypersensitivity reactions (HSRs) in patients 
receiving cisplatin was first described in the 1970s in pa-
tients who had been retreated with this drug (10). Exten-
sive use of platinum compounds in chemotherapy during 
the last decade has led to a significant increase in the in-
cidence of HSRs. Hypersensitivity to carboplatin is rarely 
observed during the first course of treatment (11,12). 
During the first five cycles, the overall risk is less than 1% 
and it rises sharply to 6.5% with the sixth cycle and has 
been reported as high as 27% in patients receiving more 
than seven cycles of treatment (13,14). The incidence of 
cisplatin hypersensitivity exhibits similar characteristics 
to those observed with carboplatin. It seems to range from 
5% to 20% and increases with concomitant radiation (11).
Case report
A 50-year-old female was admitted to the emergency de-
partment (ED) with shortness of breath, tachypnea, rest-
less, agitation, and lethargy. She had a history of cervix 
cancer during the past 2 months and had undergone to-
tal hysterectomy and chemotherapy. She was treated with 
carboplatin and taxol for the first cycle. Unfortunately, 
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Abstract
Cisplatin was the first of the platinum drugs. Second-generation platinum derivative 
was carboplatin that its efficacy in the treatment of many malignancies is equal to 
cisplatin, and its toxicity profile is more favorable. Here we report on a 50-year-old 
woman with a history of cervix cancer who developed a severe hypersensitivity reaction 
(HSR) to carboplatin. She was admitted to the emergency department (ED) with 
shortness of breath, tachypnea, restless, agitation, and lethargy. On arrival, the patient 
was hemodynamically unstable; we initiated treatment immediately with hydration, 
oxygen therapy with mask, hydrocortisone, midazolam, and adrenalin. After 1 hour, BP 
and O2 sat improved to 100/70 mm Hg and 92% respectively, but there was not any 
significant improvement in tachycardia as well as tachypnea and she was still lethargic 
and agitated. Her symptoms improved gradually after 18 hours of admission. She was 
discharged after 36 hours. HSRs to cisplatin and carboplatin can be potentially life-
threatening. The symptoms can range from a mild rash to severe anaphylaxis. Doctors 
should be aware of these reactions, determine appropriate treatment, and know the 
cross-reactivity among these drugs.
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she experienced severe HSR during infusion of carbopl-
atin. This reaction occurred during one fifth of the way 
through a 700-mg car boplatin infusion. The palpitation 
and short of breath was controlled with 200 mg intra-
venous hydrocortisone. Therefore, in the second cycle, 
carboplatin changed to cisplatin, and hydrocortisone 100 
mg IV, cimetidine 200 mg IV and chlorpheniramine IM 
were injected before administration. However, she expe-
rienced severe HSR again with hypotension, palpitation, 
and shortness of breath during administration of cisplatin. 
This reaction occurred during one half of the way through 
a cisplatin. She referred to us immediately. On arrival, the 
patient was hemodynamically unstable. Oral temperature 
was 36.3°C, pulse rate 152 beats per minute with a normal 
rhythm, blood pressure 90/60 mm Hg, and his respiratory 
rate was 26 breaths per minute with no abnormal breath 
sounds. The initial oxygen saturation was 75% (in room 
air). She was confused and somnolent with apparent re-
spiratory distress. A 12-lead electrocardiogram revealed 
sinus tachycardia at a rate of 152 bpm, a complete blood 
count was normal except for a mildly elevated white blood 
cell count of 11.6-103/mL (11.6-109/L), hemoglobin 11.2 
g/dL. His serum blood urea nitrogen, creatinine, creati-
nine kinase, and liver function tests were normal. Coagu-
lation studies, including a prothrombin time and activated 
partial thromboplastin time, were normal. Serum glucose 
was 110 mg/dL. There was respiratory alkalosis in arterial 
blood gases analysis. We initiated treatment immediately 
with hydration (normal saline 1 L in 1 hour ), O2 7 L/
min with mask, hydrocortisone 200 mg and midazolam 2 
mg IV slowly and adrenalin 0.4 mg (1:1000) IM. After 1 
hour, BP and O2 sat improved to 100/70 mm Hg and 92% 
respectively, but there was not any significant improve-
ment in sinus tachycardia as well as tachypnea and she 
was still lethargic and agitated. After 3 hours with regard 
to any improvement in the level of consciousness, brain 
computed tomography (CT) scan was performed and due 
to doubtful hyperdense lesion, brain magnetic resonance 
imaging (MRI) was performed too in which it was nor-
mal. Her symptoms improved gradually after 18 hours of 
admission and became normal after 24 hours. The patient 
was observed for 36 hours and discharged after oncology 
consultation for outpatient follow-up.
Discussion 
HSRs have been reported to carboplatin too. Carboplatin 
has a black box warning: “Anaphylactic-like reactions may 
occur within minutes of admin istration. Epinephrine, 
corticosteroids, and antihistamines may alleviate symp-
toms.” Several reports have indicated switching to cispl-
atin without the complications of a HSR (15). Cisplatin 
also has a black box warn ing: “Anaphylactic-like reactions 
have occurred. Facial edema, bronchocon striction, tachy-
cardia, and hypotension may occur within minutes of cis-
platin administration. Epinephrine, cortico steroids, and 
antihistamines have been effectively employed to alleviate 
symp toms (16). Although hypersensitivity to cisplatin has 
been reported to occur in 1% to 20% of patients, carbopla-
tin has rarely been implicated as a cause of HSRs (17,18). 
Platinum hypersensitivity symptoms may develop acutely 
during infusion or within minutes, hours, or days after the 
infusion, in patients receiving carboplatin, the number of 
prior platinum treatments and total lifetime exposure is 
associated with the possibility of hypersensitivity (12). We 
believe there was a hypersensitivity and cross-reactivity to 
both carboplatin and cisplatin in this case, although some 
studies have reported safely administration of cisplatin in 
patients with a history of carboplatin-allergic reactions 
(19-21). Successful replacement of carboplatin by cispla-
tin has been demonstrated in women with gynecological 
malignancies but the true incidence of cross-reactivity be-
tween platinum salts is not yet known. The possibility of 
developing a reaction to the platinum group agent may be 
as high as 25% and cases of fatal cisplatin reactions after 
carboplatin hypersensitivity have been reported (20,22). 
Kook et al (13) in 1998 reported on an 8-year-old girl 
with life-threatening carboplatin hypersensitivity during 
conditioning for autologous peripheral blood stem cell 
(PBSC) transplantation. Five minutes after starting the 
infusion when a total of about 10 mg of carboplatin had 
been administered, she suddenly developed tachypnea, 
chest tightness, cyanosis, vomiting, cough, hemoptysis, 
and hypotension. The infusion was immediately inter-
rupted and she was resuscitated with oxygenation, fluid 
therapy, steroids, and antihistaminic. The chest x-ray, 
showing bilateral, widespread pulmonary infiltrates along 
with hemoptysis, suggested diffuse pulmonary hemor-
rhage, echocardiogram showed reduced cardiac contrac-
tility with wall dyskinesia, she was further treated with l-
carnitine. Five days after the episodes, follow-up echocar-
diography disclosed normalization of cardiac contractil-
ity. One week later, she was readmitted to undergo PBSC 
transplantation. Skin test to carboplatin was negative. The 
same conditioning regimen was used. Carboplatin was 
administered successfully after premedication with an 
oral dose of diphenhydramine 50 mg and 3 doses of pred-
nisolone 25 mg, 13, 7 and 1 hour beforehand (13). Shlebak 
et al (23) in 1995 reported a 49-year-old woman with re-
lapsing ovarian cancer who developed a HSR to carbopla-
tin and, subsequently, to cisplatin. This patient was known 
to be allergic to co-amoxiclav and talc, both giving rise to 
a transient macular skin rash, but had no other history of 
atopy. They concluded that hypersensitivity to carbopla-
tin, switching to cisplatin-containing cytostatic regimens 
was tolerated well in most, but not in all patients. Windom 
et al (24) in 1992 reported a case of successful retreatment 
with carboplatin after desensitization in a patient with 
ovarian adenocarcinoma. Abe et al (25) in 2010 reported 3 
cases of HSRs to platinum-based chemotherapy drugs that 
required platinum readministration. Two patients (case 1 
and 2) were treated with the desensitization protocol suc-
cessfully without developing heart rate (HR) during the 
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subsequent 3 courses. These cases show the usefulness 
and effectiveness of the desensitization protocol for the 
continuation of platinum treatment in patients who have 
undergone an extended number of treatments.
Conclusion
HSRs to cisplatin and carboplatin can be a potentially 
life-threatening complication. These reactions have been 
increased due to the growing use of these agents in che-
motherapy. The symptoms can range from a mild rash to 
severe anaphylaxis. Doctors should be aware of these re-
actions, determine appropriate treatment, and know the 
cross-reactivity among these drugs. Desensitization and 
skin testing can be helpful to avoid life-threatening acci-
dents.
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